Responses
Regular and young investigator award abstracts
Clinical trials completed
278 Phase I clinical trial evaluating the safety of ADP-A2M10 SPEAR T-cells in patients with MAGE-A10+ advanced non-small cell lung cancer
Compose a Response to This Article
Other responses
No responses have been published for this article.